Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ...

Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the ...

Pfizer (PFE) closed at $25.24 in the latest trading session, marking a -1.71% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Elsewhere, the ...

As the financial landscape continues to evolve, investors are keenly monitoring key market players and economic indicators. In this article, we delve into the latest updates from the Zacks Analyst ...

If nominal GDP and earnings growth accelerate due to higher inflation, stocks’ valuation may see a support ahead, according ...

CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues ...

European shares ended at a more-than-eight-month high on Monday as positive data from Moderna Inc's COVID-19 vaccine boosted investor confidence in a faster pace of economic revival, while signs of ...

Shutdown-related data delays, Fed meeting minutes, remarks from top Fed and government officials, Amazon Prime Big Deal Days, ...

The United States may still face a wave of debt defaults and "significant declines" in asset prices because of the coronavirus pandemic and recession, the Federal Reserve warned on Monday, in a stark ...